Skip to main content
Clinical Trials/NCT05147311
NCT05147311
Completed
Not Applicable

Randomized Trial of a Positive Psychology Intervention for Patients With Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation

Brigham and Women's Hospital1 site in 1 country72 target enrollmentNovember 17, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hematologic Malignancy
Sponsor
Brigham and Women's Hospital
Enrollment
72
Locations
1
Primary Endpoint
Feasibility Rate
Status
Completed
Last Updated
last year

Overview

Brief Summary

The main purpose of this research study is to determine if a positive psychology-based program in people who have received a stem cell transplant for blood cancer treatment is feasible and acceptable, and can help improve positive feelings, mood, quality of life, overall wellbeing and health.

The Positive psychology for Allogenic Transplantation of Hematopoietic stem cell intervention (PATH), a novel 9-week phone-administered Positive psychological intervention (PPI).

Detailed Description

Low levels of positive psychological well-being (PPWB) (e.g., optimism, positive affect) in allogeneic hematopoietic stem cell transplant (HSCT) recipients are common and have been associated with decreased quality of life, poorer immune response, and increased mortality. These poor health outcomes are likely mediated through deficits in health behaviors (e.g., medication adherence, physical activity), and indeed low PPWB has been prospectively associated with poorer adherence to diet, medication, and physical activity in other medical populations, independent of sociodemographic, medical comorbidity, and the ill effects of depression and anxiety. Positive psychological interventions (PPIs) could be used to promote PPWB in the allogeneic transplant population. Despite the successful and effective use of PPIs in medical populations to reduce distress, increase quality of life, and promote health behaviors, PPI have never been tested in allogeneic recipients. -This a single center randomized trial of the PATH intervention versus usual care in patients with hematologic malignancies undergoing HSCT. The research study procedures include screening for eligibility: * Participants will be randomized equally to the two arms using randomized permuted blocks of sizes two and four, with randomization stratified by presence/absence of graft-versus-host disease (GVHD), as allogeneic transplant recipients with GVHD have significantly different courses of recovery, QOL, and function post transplant. * Participant will be randomized into either: The Positive psychology for Allogenic Transplantation of Hematopoietic stem cell intervention (PATH), a novel 9-week phone-administered Positive psychological intervention (PPI) or usual care. It is expected that about 70 people will take part in this research study. The National Institute of Health (NIH), National Cancer Institute (NCI) is supporting this research study by providing funding for the research

Registry
clinicaltrials.gov
Start Date
November 17, 2021
End Date
August 28, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hermioni L.Amonoo, MD, MPP, MPH

Physician

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult patients (≥ 18 years) with hematologic malignancies who have received allogeneic HSCT at Dana Farber Cancer Institute who are approaching 100-day post-transplant milestone.
  • Ability to speak, read and write English.
  • Access to a telephone.

Exclusion Criteria

  • Cognitive deficits impeding a study participant's ability to provide informed consent or participate adequately in the study procedures assessed via a commonly used 6-item cognitive assessment with the Brief Interview for Mental Status (BIMS).
  • Medical conditions precluding interviews.
  • Patients undergoing HSCT for benign hematologic conditions.
  • Patients undergoing outpatient HSCT.
  • Patients with psychiatric or cognitive conditions which the treating clinicians believes prohibits compliance with study procedures.
  • Patients who are unable to verbally consent or are not yet adults (including infants, children, teenagers), pregnant women, or prisoners.

Outcomes

Primary Outcomes

Feasibility Rate

Time Frame: 9 weeks

Feasibility was defined a \>75% of enrolled participants in the PATH group completing at least 6 of the 9 positive psychology sessions.

Secondary Outcomes

  • Mean Quality of Life Scores(At baseline (registration) and then week 9 (+/- 1 week) and week 18 (+/- 1 week) from the time of registration)
  • Acceptability Rate(9 weeks)

Study Sites (1)

Loading locations...

Similar Trials